Popular Articles

$500,000 Gruber Neuroscience Prize Awarded To Hall, Rosbash And Young
The 2009 Neuroscience Prize of The Peter and Patricia Gruber Foundation is being awarded to Jeffrey Hall, professor of neurogenetics at the University of Maine; Michael Rosbash, professor and director of the National Center for Behavioral Genomics at Brandeis University; and Michael Young, professor and head of the Laboratory of Genetics at Rockefeller University. On October 18, at the annual meeting of the Society for Neuroscience in Chicago, Illinois, these three distinguished scientists will receive this prestigious international award for their groundbreaking discoveries of the molecular mechanisms that control circadian (daily) rhythms in the nervous system. Their research was the first to establish a simple relationship between single genes and a complex behavior.
buy viagra
Obese And Overweight Young Adults At Greater Risk Of Pancreatic Cancer
UA scientists looking at the link between BMI over a lifetime and the risk of developing pancreatic cancer found that overweight and obese young
News of the day
New York Times Examines Varying Definitions Of 'Pandemic'
"The new swine influenza virus [H1N1], which appeared suddenly after years of warning about a potential pandemic of avian influenza, upset the WHO"s assumptions that most people have the same understanding of the word pandemic," says the New York Times in a report that examines the difficultly health experts have had when attempting to agree upon what constitutes a pandemic.
Public Health

ASGT 12th Annual Meeting: Incorporate Gene Therapy To Make Stem Cell Treatment Safer, More Effective

Gene therapy should be used in tandem with stem cell therapy to enhance the reliability of stem cells, provide an opportunity to limit adverse effects and increase treatment success, according to research presented at the American Society of Gene Therapy"s 12th Annual Meeting, May 30. "Stem cell therapy offers enormous potential to treat and even cure serious diseases. But wayward stem cells can turn into a runaway train without a conductor," said Ronald G. Crystal, MD, chief of the Division of Pulmonary and Critical Care Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center. "This is an issue that can be dealt with and we have the technology to do that in the form of gene therapy." The challenges with stem cells are unique - once a transplant is performed, the cells go to work on their own, leaving the therapist without control of the therapy"s outcome. Gene therapy, however, provides a means for predetermining, and controlling, how the implanted stem cells will react in the patient. After implantation, stem cells multiply and differentiate into new types of cells. This ability is what gives them their unique potential as medical treatment. But problems arise when the cells differentiate incorrectly, multiply excessively, migrate to new areas of the body or form tumors. By modifying the genetic code of these cells prior to transplantation, researchers can program the cells to prevent adverse effects or self-destruct should they go awry. A couple of recent events have cast a new urgency on this research. In January, the Food and Drug Administration approved the first human trials using embryonic stem cells and, in March, the Obama administration reversed an earlier policy restricting federal funding for embryonic stem cell research. Scientists believe these steps will lead to accelerated development of stem cell therapies. Stem cells hold promise for treating a host of common diseases, including diabetes, Parkinson"s disease, cancer and others. The American Society of Gene Therapy (ASGT) 12th Annual Meeting is the world"s largest scientific meeting surrounding the latest developments in gene and cell therapy, attended by nearly 2,000 researchers from around the world and featuring 60 scientific presentations. ASGT


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):